The Brain, the Ultrasound, and the Herb You've Never Heard Of

Episode Script

Thanks Toni. We've got a lot of ground to cover today, so let's get into it.

All three of today's items came out of ovarian health research — different corners of it, but they connect back to questions a lot of you are already asking about your ovaries, your brain, and what happens when estrogen leaves the picture. I want to be upfront: none of today's items are lifestyle tips or "here's what to do differently." This is a science episode. Some of it is early-stage. Some of it is genuinely important. I'll tell you which is which.

---

Start with the ultrasound story, because this is the one with the most direct relevance to women going through perimenopause and menopause who end up with an ovarian cyst on an imaging report.

If you've ever had a pelvic ultrasound and heard the words "we found something on your ovary," you know the particular dread that follows. Most of the time — the vast majority of the time — ovarian cysts in premenopausal women are completely benign, functional cysts that come and go with your cycle. But in perimenopause and after menopause, the calculus changes a little. Your ovaries aren't cycling the same way, so a cyst that shows up gets looked at more carefully.

The problem has always been: how do you tell the difference between a cyst that's totally fine and one that warrants surgery or closer surveillance? You don't want to operate on something that was never going to hurt anyone. You also don't want to miss something that was.

There's a scoring system that radiologists already use for this called O-RADS — Ovarian-Adnexal Reporting and Data System. Think of it like the scoring systems radiologists use for mammograms. It's a standardized way of describing what they see on the ultrasound and assigning a risk category. A 2026 paper from Liu and colleagues looked at whether adding a separate risk calculation tool — called the Risk of Malignancy Algorithm — into the O-RADS framework made the whole system better at telling cancerous from non-cancerous masses.

The short version of what they found: yes, combining the two approaches improved accuracy compared to either one alone. The integrated system got better at correctly identifying which masses were likely malignant and which weren't.

Now, a few things worth knowing before you walk away thinking this is solved. This is a single study, and these kinds of imaging studies need to be validated across different populations and different imaging centers before they change standard practice. The radiologist reading your ultrasound is not necessarily using this modified framework yet — it's research, not yet protocol. And ultrasound is not a definitive cancer screening tool in the way that, say, a biopsy is. It helps direct next steps. It is not a verdict.

But the underlying problem this is trying to solve is real and important. Right now, a meaningful number of women undergo surgery to remove ovarian masses that turn out to be benign. That's surgery with real risks and recovery time. And on the other side, some cancers get caught later than they should. Better risk stratification at the imaging stage — being smarter about sorting low-risk from high-risk before anyone goes under anesthesia — matters. This study is one piece of that effort.

---

The second item is a case report, and I want to explain why I'm covering it even though case reports sit at the very bottom of the evidence hierarchy. Usually I'd tell you to be skeptical of case reports because they're literally a story about one patient. They can't prove causation, they can't tell you about typical outcomes. One person's experience is not a clinical trial.

This one is worth covering for a different reason.

The cancer in question is called small cell carcinoma of the ovary, pulmonary type. The name is a mouthful, but what it means is: a rare type of ovarian cancer that behaves a lot like the aggressive small cell lung cancer you may have heard of. This is not the same as the more commonly discussed small cell carcinoma of the ovary hypercalcemic type — that one gets the most research attention. The pulmonary type is rarer still, and historically, survival rates at advanced stages have been extremely poor.

The patient in this 2026 case report had stage IVB disease. Stage IV means the cancer had spread beyond the ovary. Stage IVB specifically means it had spread to distant organs. At that stage, with this type of cancer, long-term survival is unusual enough that reporting it in detail actually contributes something to what doctors know.

The treatment path included complete cytoreduction — which means surgery to remove as much tumor as possible, ideally all visible disease — followed by chemotherapy. When the cancer came back, the team tried re-challenging with platinum-based chemotherapy, which is the chemo backbone for ovarian cancer treatment, instead of immediately moving to different drugs. The patient achieved long-term survival.

Why does this matter? Because with cancers this rare, there's no large randomized trial telling doctors what to do. Oncologists making decisions for these patients are drawing on case series, small cohort studies, and yes, individual case reports like this one. Each detailed report of what was tried and what happened adds to a very thin body of evidence. The authors of this paper are contributing to a living record that the next oncologist treating this cancer will actually look at.

I want to be clear that one case cannot tell us this approach works for everyone, or even for most people with this diagnosis. What it tells us is that complete cytoreduction followed by platinum re-challenge produced long-term survival in this patient, and that's worth documenting. For anyone whose life has been touched by a rare gynecologic cancer — yours or someone you love — the seriousness with which researchers track even single cases is part of why progress happens at all.

---

The skullcap study. Okay.

The plant is Scutellaria — common name skullcap. It's used in traditional Chinese medicine, and it contains compounds called flavonoids. Flavonoids are a large family of plant chemicals found in everything from berries to tea to red wine. Some have antioxidant and anti-inflammatory effects in lab settings. Researchers extracted specific flavonoids from Scutellaria and tested them in rats that had undergone ovariectomy — surgical removal of the ovaries — combined with a chemical called D-galactose that accelerates aging-related changes in the brain. The idea was to create an animal model of menopause-related cognitive decline, then see whether the skullcap compounds could reverse or reduce the memory impairment.

They found improvement in memory function in the treated rats compared to untreated rats with the same induced conditions.

This is interesting basic science. I'll say that genuinely, not as a hedge. Understanding the mechanisms by which estrogen loss affects brain function — and what might interfere with those mechanisms — is a legitimate and important area of research. The cognitive symptoms of menopause are real and underresearched. Women report brain fog, word-finding problems, and memory slips during perimenopause, and the science on why that happens and what helps is still catching up to the experience.

But I want to be direct about what this study is and isn't. This is a rat study. Rats with surgically removed ovaries are a model for studying menopause, but they are not the same as a woman going through perimenopause over years. The chemical memory impairment induced in these animals is a model, not a precise replica of what happens in the human brain during hormonal transition. And animal studies on cognitive function have a genuinely poor track record of translating into effective human treatments. The history of Alzheimer's research alone could fill a whole episode on this — dozens of compounds that looked promising in mouse models and failed in human trials.

So my actual position on this: worth watching. Not worth supplementing based on. If you've seen skullcap extracts marketed for menopause brain fog, this study does not validate that product. The study was conducted in rats, the doses and delivery were controlled in a lab setting, and there is no human trial data behind those products. What this study contributes is a clearer picture of one possible mechanism — and maybe a rationale for funding a human trial. That's meaningful. It's just not the same as evidence that taking skullcap helps you remember where you put your keys.

The brain-fog piece of menopause deserves serious research attention, and it's finally getting some. Studies like this one are part of how the field builds toward something clinical. The gap between "promising in rats" and "proven in people" is where most things die — and the supplement industry banks on most consumers not knowing that gap exists.

---

Sources curated automatically by the Hot Flasher pipeline.